The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. (Q51768181)
Jump to navigation
Jump to search
scientific article published on 4 December 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. |
scientific article published on 4 December 2013 |
Statements
The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss (English)
Betty Y Chang
Joseph J Buggy
Yusuke Nagai
Tatsuhiko Kodama
Hiroshi Asahara
Hiroshi Takayanagi